Dopamine in substantia nigra and cortex after gamma-butyrolactone treatment.
D015107:4-Butyrolactone / Q000494:pharmacology*; D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005663:Furans / Q000494:pharmacology*; D008297:Male; D009411:Nerve Endings / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*
D005663:Furans; D015107:4-Butyrolactone; D004298:Dopamine; D009638:Norepinephrine